We may earn commissions from brands listed on this site. It never changes a spec, a grade, or a ranking. Disclosure
Home / Evidence / Red Light Therapy for Psoriasis: What the Evidence Shows

Red Light Therapy for Psoriasis: What the Evidence Shows

Updated August 2026 · compiled from published specifications and attributed third-party measurements

Red light therapy for psoriasis has intriguing but thin evidence: a nine-patient trial using combined 633nm and 830nm LED light reported clearance averaging around 90 percent in recalcitrant plaques, a result too small to generalize but strong enough to justify larger trials.

Evidence grade: Limited

How red light therapy acts on psoriasis

Psoriasis is an immune-driven condition where skin cells proliferate too quickly, producing inflamed, scaly plaques. Red and near-infrared light appear to act on the local immune and inflammatory signaling in the skin, dampening the pro-inflammatory environment and, in the proposed mechanism, slowing the excessive keratinocyte turnover. This is distinct from the ultraviolet phototherapy dermatologists use for psoriasis, which works through a different, DNA-level mechanism.

What the studies show

StudyDesignFinding
PMID 197648939-patient trial, 633 + 830nm LED, recalcitrant psoriasis60-100% clearance, ~92% average; illustrative, not definitive

Recalcitrant psoriasis, small combined-wavelength trial (PMID 19764893)

A nine-patient study using 633nm and 830nm together reported roughly 90 percent average clearance in psoriasis that had resisted other treatment. The result is striking but the sample is tiny, so it is best read as a promising signal that justifies larger study rather than as established efficacy. It is included here honestly, with that caveat front and center.

Which wavelengths do the work

The trial that showed benefit paired 633nm red with 830nm near-infrared, so a panel offering both surface red and dermal-depth near-infrared is the sensible match. This is one area where visible red matters, since plaques are at the skin surface, with 830nm adding a little depth.

Wavelength penetration depth (illustrative)630 and 660nm are absorbed near the skin surface; 810, 830, 850 and 1064nm penetrate into deep muscle and joints.Relative penetration depth by wavelength630nmskin tissue660nmskin tissue810nmdeep tissue830nmdeep tissue850nmdeep tissue1064nmdeep tissueIllustrative. Longer near-infrared reaches joints and deep muscle; reds work at the skin.
Wavelength penetration depth (illustrative)

Dosing: distance, time, and frequency

There is no well-established home dose for psoriasis specifically; the small trial used repeated clinic sessions. A cautious home approach mirrors general skin protocols, 10 to 20 minutes at 6 to 12 inches, several times weekly, but this is a diagnosed inflammatory condition and the dose should be discussed with a dermatologist rather than self-escalated.

Biphasic dose-response (more is not better)Response rises to an optimal dose window then falls off; higher doses can blunt the effect.The biphasic dose-responseoptimal windowtoo littletoo muchdose (J/cm2 and session length)
Biphasic dose-response (more is not better)

How it compares with conventional options

Standard psoriasis care, topical steroids and vitamin D analogues, UVB phototherapy, and systemic or biologic drugs for severe disease, is far better evidenced than red light. Red light is at most a gentle adjunct here, not a replacement, and anyone with moderate-to-severe psoriasis should be under dermatological care.

Which panel features matter for psoriasis

The studied pairing was 633nm plus 830nm together. Panels carrying both bands mirror the protocol most closely. Psoriasis is a diagnosed condition: involve the treating dermatologist before adding light therapy.

Device picks from the database

RLT Home Total Spectrum COMPACT

RLT Home Total Spectrum COMPACT

Carries 630/660 plus 830nm, the studied pairing, with published density.

Full specs
Hooga HG300

Hooga HG300

Budget option; lacks 830nm, so protocol fidelity is lower.

Full specs

What the evidence does not support

The supportive evidence is a single very small study. Red light does not cure psoriasis, does not replace prescribed treatment, and should not be used to delay proper dermatological care. Presented honestly, this is a plausible adjunct with thin evidence, graded accordingly.

Safety and contraindications

Photosensitizing medications are common in dermatology, so check interactions with a clinician. Use eye protection with bright panels, and do not apply light over broken or actively infected skin without medical guidance.

This page is general wellness information, not medical advice. Photobiomodulation research is promising but heterogeneous; trials differ in wavelength, dose, and device class. Speak with a qualified clinician, especially for diagnosed conditions.

Frequently asked questions

Is this a replacement for prescribed treatment?

No. The study population continued under clinical care; home use is adjunct territory.

Is red light the same as UV phototherapy for psoriasis?

No. Dermatological UVB phototherapy works through a different mechanism and has far stronger evidence. Red light is a gentler, much less proven adjunct.

Can red light clear psoriasis plaques?

One tiny trial reported clearance, but the evidence is thin. Treat it as a possible adjunct discussed with a dermatologist, not a cure.

Methodology: rankings weigh measured or method-stated irradiance, wavelength coverage and published density, buyer terms (trial, restocking, stand, warranty), and value per LED. No brand pays for a position. Full methodology.